MedTrace Logo

Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia

NCT07397325 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-04-13

No results posted yet for this study

Summary

Clinical Study of DA-020 as a Treatment for Chemotherapy Induced Alopecia

Conditions

  • Chemotherapy Induced Alopecia
  • Chemotherapy Side Effects

Interventions

DRUG

DA-020

7mL application of DA-020 (Topical Oxymetazoline)

DRUG

Placebo

Topical placebo solution

DRUG

DA-020 and Hyperforin

7mL application of DA-020 (Topical Oxymetazoline) and Hyperforin (1.5%)

Sponsors & Collaborators

  • Daniel Alain, Inc.

    collaborator INDUSTRY

  • Follea International Limited

    collaborator INDUSTRY

  • Applied Biology, Inc.

    lead INDUSTRY

Principal Investigators

  • Andy Goren, MD · University of Rome G. Marconi

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-16
Primary Completion
2026-10-05
Completion
2026-12-07

Countries

  • Brazil
  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07397325 on ClinicalTrials.gov